Page last updated: 2024-11-12

nivazol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

nivazol: RN given refers to (17alpha)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9910575
CHEMBL ID2106806
CHEBI ID177683
SCHEMBL ID570242
MeSH IDM0123563

Synonyms (26)

Synonym
(1s,2r,13r,14s,17r,18s)-17-ethynyl-7-(4-luorophenyl)-2,18-dimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol
CHEBI:177683
nivazol (usan)
24358-76-7
D05194
nivacortol (inn)
nivazol
win-27914
CHEMBL2106806
unii-50u0z120rs
nivazol [usan]
nivacortolum [inn-latin]
nivacortol
nivacortolum
win 27,914
2'-(p-fluorophenyl)-2'h-17alpha-pregna-2,4-dien-20-yno(3,2-c)pyrazol-17-ol
2'h-pregna-2,4-dien-20-yno(3,2-c)pyrazol-17-ol, 2'-(4-fluorophenyl)-, (17alpha)-
nivacortol [inn]
50u0z120rs ,
einecs 246-202-4
2'h-pregna-2,4-dien-20-yno(3,2-c)pyrazol-17-ol, 2'-(4-fluorophenyl)-, (17.alpha.)-
2'-(p-fluorophenyl)-2'h-17.alpha.-pregna-2,4-dien-20-yno(3,2-c)pyrazol-17-ol
SCHEMBL570242
(1s,2r,13r,14s,17r,18s)-17-ethynyl-7-(4-fluorophenyl)-2,18-dimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol
Q27260822
DTXSID301043242
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
steroidAny of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from squalene which is a triterpene.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (16.67%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]